In ₹ Crore except Per Share Latest Annual | ADVENZYMES FY26 | AARTIPHARM FY26 | AARTIDRUGS FY26 | AGARWALEYE FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | ◆ 20.04× | 43.02× | 20.46× | 118.81× | 43.02× -53% | |
| P/B | ◆ 2.01× | 3.54× | 2.57× | 7.48× | 3.54× -43% | |
| EV/EBITDA | ◆ 11.83× | 22.19× | 14.74× | 27.67× | 22.19× -47% | |
| Market Cap | ₹3,382 Cr | ₹7,516 Cr | ₹3,988 Cr | ₹15,846 Cr | ₹7,516 Cr -55% | |
| Growth | ||||||
| Revenue CAGR 3Y | ◆ 11.32% | -2.20% | -1.89% | — | -2.04% +654% | |
| Revenue CAGR 5Y | ◆ 8.24% | — | 3.55% | — | 3.55% +132% | |
| Net Income CAGR 3Y | ◆ 18.68% | -3.35% | 5.43% | — | 1.04% +1696% | |
| Revenue YoY (latest Q) | 2.08% | ◆ 38.74% | 19.01% | 25.97% | 25.97% -92% | |
| Net Income YoY (latest Q) | -4.58% | ◆ 53.82% | -7.12% | 44.56% | 44.56% -110% | |
| Profitability | ||||||
| EBITDA Margin | ◆ 30.72% | 20.29% | 12.05% | 27.38% | 20.29% +51% | |
| Net Income Margin | ◆ 23.28% | 9.60% | 7.60% | 8.08% | 8.08% +188% | |
| Return on Common Equity | 10.02% | 8.13% | ◆ 12.58% | 6.28% | 8.13% +23% | |
| Return on Capital Employed | 10.91% | 10.41% | ◆ 12.80% | 8.43% | 10.41% +5% | |
| Return on Assets | ◆ 9.44% | 5.02% | 6.92% | 4.27% | 5.02% +88% | |
| Credit & Quality | ||||||
| Total Debt/Equity | ◆ 0.01× | 0.32× | 0.37× | 0.07× | 0.32× -97% | |
| Interest Coverage | ◆ 71.91× | 5.65× | 7.19× | 3.24× | 5.65× +1173% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹746 Cr | ₹1,819 Cr | ₹2,565 Cr | ₹2,080 Cr | ₹2,080 Cr -64% | |
| Net Income | ₹174 Cr | ₹175 Cr | ₹195 Cr | ₹168 Cr | ₹175 Cr -1% | |
| Total Assets | ₹1,839 Cr | ₹3,482 Cr | ₹2,815 Cr | ₹3,942 Cr | ₹3,482 Cr -47% | |
| EPS | ₹15.08 | ₹19.27 | ₹21.36 | ₹4.21 | ₹19.27 -22% | |
| Book Value per Share | ₹150.38 | ₹234.35 | ₹169.74 | ₹66.91 | ₹169.74 -11% | |